Browse the evidence

Semaglutide (subcutaneous and oral) demonstrates cardiovascular safety (non-inferiority) and potential renal benefits in high-risk Type 2 Diabetes patients, though it may increase retinopathy complications.

For those with Type 2 Diabetes and heart disease risk, semaglutide is safe for the heart and may protect kidney function. However, patients with existing diabetic eye disease should be monitored closely as rapid blood sugar improvement can sometimes worsen retinopathy.

Antihyperglycemic therapies reduce the risk of Major Adverse Cardiovascular Events (MACE) in a glycemic-dependent manner, where every 1% reduction in HbA1c is associated with a 14% relative reduction in MACE risk.

If you have type 2 diabetes, achieving a 1% reduction in your HbA1c through medication or lifestyle is associated with a 14% lower risk of major cardiovascular events like heart attack or stroke. This benefit is consistent across various drug classes, suggesting that effective glycemic control is a primary strategy for cardiovascular protection.

GLP-1 receptor agonists provide cardiovascular protection by reducing major adverse cardiac events (MACE), independent of substantial glucose lowering, through mechanisms including improved endothelial function and reduced inflammation.

GLP-1 medications offer significant cardiovascular protection, reducing the risk of heart attack, stroke, and cardiovascular death. This benefit exists even in non-diabetic obese patients, likely due to improved blood vessel function and reduced inflammation, not just weight loss or blood sugar control.

Semaglutide 2.4 mg once weekly reduces major adverse cardiac events (MACE) in overweight or obese individuals without diabetes, demonstrating cardiovascular benefit independent of glycemic control.

If you are overweight or obese (BMI >= 27) and have existing heart disease but no diabetes, ask your doctor about the SELECT study or semaglutide treatment. This specific formulation (2.4 mg weekly) is designed to protect your heart, offering benefits that go beyond just losing weight, which alone hasn't always been enough to prevent heart events in the past.

Semaglutide 1 mg once weekly reduces major adverse renal events (MACEr) in people with Type 2 Diabetes and renal impairment, as investigated in the FLOW study.

If you have Type 2 Diabetes and early-to-moderate kidney disease, discuss the FLOW study findings with your doctor. This once-weekly injection (1 mg) is being tested specifically to protect your kidneys from failing, potentially delaying or preventing the need for dialysis.

Previous GLP-1 analogue CVOTs (albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide) demonstrate a reduction in major adverse cardiac events (MACE) and renal composite outcomes in people with Type 2 Diabetes.

If you have Type 2 Diabetes and heart disease or high risk, GLP-1 analogues (like semaglutide, liraglutide, etc.) are proven to reduce heart attacks, strokes, and cardiovascular death, in addition to lowering blood sugar.

Obesity is a significant risk factor for kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers, and 10-26% of all kidney cancers attributable to excess weight.

Maintaining a healthy weight significantly reduces your risk of developing kidney cancer. Higher body weight is linked to a 25% increase in kidney cancer risk for every 5 units of BMI increase. This risk is driven by hormonal changes and inflammation caused by excess fat tissue. Weight management is a proven strategy for cancer prevention.

SGLT-2 inhibitors and GLP-1 receptor agonists significantly reduce major adverse cardiovascular events (MACE) and end-stage kidney disease (ESKD) in Type 2 Diabetes patients, with SGLT-2i showing specific superiority for kidney outcomes.

For Type 2 Diabetes patients with heart or kidney risks, prioritize SGLT-2 inhibitors or GLP-1 RAs. These drugs do more than lower blood sugar; they significantly reduce the risk of heart attacks, heart failure hospitalizations, and kidney failure. SGLT-2 inhibitors are particularly strong for protecting the kidneys.

Semaglutide improves cardiovascular outcomes, including reducing the risk of major adverse cardiovascular events (MACE), in patients with type 2 diabetes.

If you have type 2 diabetes and heart disease, kidney disease, or heart failure, ask your doctor about adding a GLP-1 RA like semaglutide. It can significantly lower your risk of heart attack, stroke, and heart failure, even if your blood sugar is already well-controlled.

Genetically modeled GLP-1 and GIP receptor agonism reduces fatty food liking and increases vegetarian food liking.

Genetic evidence suggests that activating GLP-1 and GIP receptors shifts food preferences away from fatty foods and towards vegetarian options. This change in food preference may contribute to the observed reduction in binge drinking.

Tirzepatide treatment (10 mg or 15 mg once weekly for 72 weeks) significantly improves self-reported health-related quality of life (HRQoL) in adults with obesity or overweight and type 2 diabetes, specifically in physical functioning, bodily pain, general health, vitality, and social functioning.

If you have type 2 diabetes and are overweight or obese, treatment with tirzepatide (Mounjaro/Zepbound) can significantly improve your daily quality of life. This includes feeling less pain, having more energy, and being more socially active. The improvements are seen in both physical and mental well-being, and they are greater for those who lose more weight. Talk to your doctor about whether this once-weekly injection is right for you, especially if you are struggling with physical limitations due to your weight.

Glucagon regulates glucose and amino acid homeostasis and counters hypoglycemia.

Glucagon is a natural hormone that helps keep your blood sugar and amino acid levels stable. It acts as a counter-regulatory mechanism to prevent hypoglycemia, making it essential for metabolic balance.

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk.

If you have Type 2 Diabetes and are at high risk for heart problems, ask your doctor about GLP-1 RAs like liraglutide or semaglutide. These drugs not only help control blood sugar but have been proven in major studies to significantly lower your risk of heart attack, stroke, and cardiovascular death. The benefits extend beyond glucose control to direct heart protection.

Obesity is a chronic disease driven by dysfunctional adipose tissue and dysregulated energy homeostasis, requiring medical treatment rather than solely lifestyle changes.

Obesity is a medical condition, not a moral failing. If you have obesity, you need medical treatment, not just willpower. Seek a doctor who understands this and offers evidence-based therapies.

Naltrexone/bupropion combination therapy produces moderate weight loss (up to 6.1% vs placebo) and improves metabolic markers, but carries risks of seizures and psychiatric side effects.

This medication can help you lose weight by affecting brain chemicals that control hunger. It is taken twice daily and must be started at a low dose to avoid side effects like nausea, constipation, or headaches. It is not suitable for people with a history of seizures, eating disorders, or heart problems. You must stop the medication if you do not lose at least 5% of your body weight after 12 weeks.

Metformin is the first-line pharmacological treatment for T2DM and prediabetes, offering significant reduction in microvascular complications and diabetes-related deaths through mechanisms including inhibition of hepatic gluconeogenesis and increased insulin sensitivity.

Metformin is the standard first-line drug for T2DM and prediabetes. It reduces complications and deaths. If you experience stomach upset, ask your doctor about slow-release versions or slow titration to manage side effects.

SGLT2 receptor inhibitors (SGLT2R-i) provide significant cardiovascular and renal benefits, including reduced cardiovascular mortality and heart failure hospitalization, in addition to glycaemic control, by preventing glucose reabsorption in the kidneys.

SGLT2 inhibitors (like empagliflozin or dapagliflozin) are powerful drugs for T2DM patients with heart or kidney risks. They significantly reduce heart failure hospitalizations and mortality. Maintain good hygiene to minimize the risk of genital infections.

Obesity acts as an independent risk factor and driver for cardiovascular diseases through mechanisms including insulin resistance, endothelial dysfunction, systemic inflammation, and neurohormonal activation, leading to hypertension, heart failure, coronary artery disease, and stroke.

High body weight is a major biological driver of heart disease, not just a cosmetic issue. Addressing it requires medical and public health strategies, not just willpower, because it triggers harmful biological changes like inflammation and high blood pressure.

GLP-1 receptor agonists (e.g., semaglutide) and dual agonists (e.g., tirzepatide) are effective pharmacotherapies for obesity, achieving 10-20% mean body weight reduction, but their use is limited by stigma, regulatory barriers, and lack of insurance coverage.

If you have obesity, ask your doctor about GLP-1 receptor agonists (like semaglutide) or dual agonists (like tirzepatide). These are proven to help with significant weight loss. If insurance doesn't cover them, advocate for policy changes or look for patient assistance programs.

GLP-1 receptor agonists (GLP-1RAs) induce weight loss primarily through central nervous system (CNS) mechanisms, specifically by acting on GLP-1 receptors in the dorsal vagal complex (NTS and area postrema) and hypothalamic nuclei, rather than through peripheral signaling alone.

GLP-1 medications like semaglutide work by signaling to your brain to reduce hunger and food intake, not just by slowing digestion. Understanding this brain-gut connection helps explain why these drugs are effective for weight loss and why side effects like nausea occur via specific brain pathways.

For patients with Class II obesity (BMI 35-39.9 kg/m2), tirzepatide is significantly superior to other medications and endoscopic procedures, but its weight loss efficacy is inferior to major surgeries like Roux-en-Y gastric bypass (RYGB) and One-Anastomosis Gastric Bypass (OAGB).

If you have Class II obesity (BMI 35-39.9), surgery (like gastric bypass) will likely help you lose more weight than medication. However, if you are not ready for or cannot undergo surgery, newer medications like tirzepatide are still significantly more effective than other non-surgical options, though they will not achieve the same level of weight loss as surgery.

Once-weekly subcutaneous semaglutide at 2.4 mg significantly improves heart failure symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, independent of weight loss mechanisms.

For patients with HFpEF and obesity, once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, exercise capacity, and quality of life. This treatment addresses a major unmet need in this population, offering benefits beyond weight loss alone. Patients should discuss this option with their healthcare provider, considering the potential for gastrointestinal side effects and the significant clinical improvements observed.

SGLT2 inhibitors (specifically empagliflozin) reduce major adverse cardiovascular events (MACE) and cardiovascular death in patients with Type 2 Diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and established cardiovascular disease, empagliflozin (10 or 25 mg daily) can significantly reduce your risk of major cardiovascular events and cardiovascular death. This benefit is observed even in patients with moderately reduced kidney function (eGFR > 30). The mechanism is likely related to hemodynamic changes rather than just glucose lowering.

GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.